Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00906074
Other study ID # B1811046
Secondary ID 3074A1-4463
Status Completed
Phase N/A
First received May 19, 2009
Last updated May 9, 2012
Start date February 2009
Est. completion date November 2010

Study information

Verified date May 2012
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority Spain: Ethics Committee
Study type Observational

Clinical Trial Summary

This is an observational study to evaluate the relative importance of the known risk factors for severe surgical site infections (SSIs) on the development of the more severe SSI cases, and to describe the demographic, clinical features, etiology and the management and outcome of patients suffering from severe SSIs in Spain.


Description:

Case and Control study.


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date November 2010
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age of or above 18 years.

- Admitted to a General Surgery Ward for elective or emergency abdominal surgery.

- Contaminated or dirty-infected surgical procedures.

- Only for cases, they will have to present symptoms and signs of a surgical site infection (SSI) (within 0-30 days) after abdominal surgery.

- Only for controls, patients must be free of SSI after 30 days from surgery, regardless of whether they are still in the hospital or being observed as an outpatient in the external clinic.

Exclusion Criteria:

- Age under 18 years.

- American Society of Anesthesiologist (ASA) score of 5 or above.

- Surgical implant in place.

- Clean or clean-contaminated surgical procedures.

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Intervention

Procedure:
Elective or emergency abdominal surgery
Clinical record review.
Elective or emergency abdominal surgery
Clinical record review

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Pre-surgical Morbidities Morbidities (risk factors) included: neoplasm, tobacco use, body mass index (weight in kilograms divided by height in meters squared [BMI kg/m2]) greater than (>) 30, diabetes mellitus (DM), immunosuppression/ corticosteroids, anemia (hemoglobin [Hb] less than (>) 9 grams per deciliter [gr/dL]) or malnutrition (hypoalbuminemia). Baseline (Pre-surgical) No
Primary Percentage of Participants Who Received Pre-surgical Antibiotic Prophylaxis Baseline (Pre-surgical) No
Primary Percentage of Participants Who Underwent Emergency Surgery or Scheduled Surgery Day 0 (day of surgery) No
Primary Percentage of Participants With Classification of Risk of Surgical Infection of Clean-contaminated, Contaminated or Dirty Surgical infection risk class: Clean-contaminated: controlled entry in normally colonized body cavities/no unusual contamination/minimum fluid discharge/minimal sterile technique violation/re-surgery on clean surgical incision within 7 days/negative surgical exploration through intact skin. Contaminated: no acute inflammation/purulent discharge/significant fluid/material violation of sterile technique/penetrating trauma less than 4 hours old/graft in chronic skin wounds. Dirty: pus-abscess drainage/ preoperatively colonized body cavity perforated/penetrating trauma more than 4 hours old. Day 0 (day of surgery) No
Primary Type of Surgeon Surgical speciality of physician who performed surgery. Day 0 (day of surgery) No
Primary Percentage of Participants With Infection Microorganism infection by bacterial type. Day 0 (day of surgery) up to 30 days post surgery No
Primary Percentage of Participants Who Showed Clinical Improvement of SSI Clinical improvement of SSI was defined as healed (signs and symptoms of initial infection resolved) or improved (initial signs and symptoms significantly diminished without the appearance of new signs). Day 0 (day of surgery) up to 30 days post surgery No
Primary Percentage of Participants With Post-surgical Drainage Day 0 (day of surgery) up to 30 days post surgery No
Secondary Percentage of Participants Whose National Nosocomial Infection Surveillance System (NNISS) Scores of Preoperative Risk of Infection Were Greater Than >0 Percentage of participants with NNISS score for increased preoperative risk of infection. Baseline (pre-surgical) No
Secondary ASEPSIS Classification in Participants With Serious SSI Additional treatment, Serous discharge, Erythema, Purulent exudate, Separation of deep tissue, Isolation of bacteria, Stay in hospital prolonged over 14 days (ASEPSIS). ASEPSIS classification is a numerical indication of wound healing progress: satisfactory healing (0-10), disturbance of healing (11-20), minor wound infection (20-30), moderate wound infection (30-40), and severe wound infection (over 40). Up to 30 days post surgery No
Secondary Classification of SSI Infection Participants with organ-space or deep incisional SSI. Day 0 (day of surgery) up to 30 days post surgery No
Secondary Percentage of Participants Who Had Microbiologic Resolution of SSI (Sensitivity of Microorganisms to Antibiotics) Resolution of SSI ranged from eradication (infection cured) to persistence (infection continued). Day 0 (day of surgery) up to 30 days post surgery No
Secondary Number of Participants With Antimicrobial Resistance Microbiological resistance reported for microorganisms that were found at a frequency greater (>) than 5 percent (%). Day 0 (day of surgery) up to 30 days post surgery No
See also
  Status Clinical Trial Phase
Completed NCT05529173 - Povidone-Iodine for Nasal Decolonization Phase 4
Recruiting NCT03295955 - Comparing Efficacy of Postoperative Oral Antibiotic Use in Trans-Oral Thyroidectomy N/A
Not yet recruiting NCT05276687 - Efficacy of Diluted Betadine vs Antibiotic Installation Before Surgical Wound Closure in Prevention of Post Cardiac Surgery Wound Infection Phase 4
Completed NCT02776774 - Topical Antibiotic Treatment for Spine Surgical Site Infection
Terminated NCT00386477 - Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial N/A
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT05077592 - Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections Phase 4
Completed NCT03148067 - Incidence and Risk Factors for Surgical Site Infection After Intramedullary Nailing of Femoral and Tibial Fractures
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Completed NCT01890720 - Incisional Negative Pressure Wound Therapy for Prevention of Postoperative Infections Following Caesarean Section N/A
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2
Completed NCT02919410 - Bacterial Colonization With and Without Iodophor-impregnated Adhesive Drapes in Hip Surgery: a Prospective, Randomized Trial N/A
Completed NCT02020018 - Negative Pressure Wound Therapy for Prevention of Poststernotomy Infection N/A
Completed NCT01741649 - Clorhexidine Versus Povidone for the Prevention of Surgical Site Infection After Cesarean Section N/A
Not yet recruiting NCT01457859 - Effectiveness of Triclosan Coated Sutures in Preventing Leg Wound Infection After Coronary Artery Bypass Surgery Phase 4
Completed NCT01340534 - Supplemental Perioperative Oxygen to Reduce the Incidence of Post-cesarean Wound Infection Phase 3
Completed NCT03365219 - Alexis O-Ring Wound Retractor for the Prevention of Post-cesarean Surgical Site Infections N/A
Completed NCT01026259 - Local Warming of Surgical Incisions Phase 3
Completed NCT03574090 - Study the Efficacy of Topical Antibiotherapy in the Prophylaxis of Incisional Surgical Infection in Colorectal Surgery Phase 4
Completed NCT03199911 - Topical Antibiotic Prophylaxis for Eyelids Phase 4